P1694: COST-EFFECTIVENESS OF AXICABTAGENE CILOLEUCEL VS. TISAGENLECLEUCEL FOR THE TREATMENT OF RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA: UPDATED SURVIVAL RESULTS FROM THE ZUMA-1 AND JULIET TRIALS

• Olalekan Oluwole,
• Markqayne Ray,
• Neil Davies,
• Rory Bradford,
• Calum Jones,
• Anik Patel,
• Frederick Locke

Affiliations

Olalekan Oluwole

1 Vanderbilt University Medical Center, Nashville, United States

Markqayne Ray

2 Kite, A Gilead Company, Santa Monica, United States

Neil Davies

3 Mtech Access, Cheadle Hulme, United Kingdom

Rory Bradford

3 Mtech Access, Cheadle Hulme, United Kingdom

Calum Jones

3 Mtech Access, Cheadle Hulme, United Kingdom

Anik Patel

2 Kite, A Gilead Company, Santa Monica, United States

Frederick Locke

4 H Lee Moffitt Cancer Center, Tampa, United States